D. Gentien

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
D Gentien, D. Gentien, David Gentien
Publication record
180 papers · 6,315 citations · H-index 42

PAPERS

Molecular and cellular composition changes after neoadjuvant letrozole and palbociclib in early luminal breast cancer
20260 citationsauthor #7
Abstract 4997: The ROSALIND Study: Identifying multi-omic signatures in long-term cancer survivors for therapeutic target discovery
20250 citationsauthor #4
Abstract P2-03-29: Upregulation of senescence signatures and interferon-signalling after short-term pre-operative CDK4/6 inhibitor – gene expression analysis from the POP and ABC-POP trials
20250 citationsauthor #6
Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons
20247 citationsauthor #17
MDB-12. NANOPORE SEQUENCING AS A CUTTING-EDGE TECHNOLOGY FOR MEDULLOBLASTOMA CLASSIFICATION
20240 citationsauthor #9
Plakins are involved in the regulation of centrosome position in polarized epithelial cells
20241 citationsauthor #3
4MO Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: A translational analysis
20240 citationsauthor #7
Nanopore Sequencing as a Cutting-Edge Technology for Medulloblastoma Classification.
20242 citationsauthor #11
Optical Genome Mapping for detecting Homologous Recombination Deficiency (HRD) in human breast and ovarian cancers
20240 citationsauthor #5
Non-invasive multi-cancer diagnosis using DNA hypomethylation of LINE-1 retrotransposons
20240 citationsauthor #16
Plakins are involved in the maintenance of epithelial polarity
20230 citationsauthor #3
Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
202314 citationsauthor #1
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
20235 citationsauthor #3
Evidence of inter‐ and intra‐keloid heterogeneity through analysis of dermal fibroblasts: A new insight in deciphering keloid physiopathology
202311 citationsauthor #8
Progression‐associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis
202316 citationsauthor #8
HORMAD1 overexpression predicts response to anthracycline–cyclophosphamide and survival in triple‐negative breast cancers
20236 citationsauthor #17
Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.
202292 citationsauthor #9
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.
202231 citationsauthor #16
Abstract GS1-10: Clinical utility of molecular tumor profiling: Results from the randomized trial SAFIR02-BREAST
202214 citationsauthor #16
Multi-omics comparison of malignant and normal uveal melanocytes reveals novel molecular features of uveal melanoma
20220 citationsauthor #1
Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation
20225 citationsauthor #5
Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic
202214 citationsauthor #10
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks
202215 citationsauthor #15
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast
202114 citationsauthor #9
A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial
202125 citationsauthor #12
A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression
202187 citationsauthor #26
Abstract PS7-31: Breast cancer risk assessment combined with a polygenic risk score in the general population for personalized screening
20210 citationsauthor #9
Reference standards for gene fusion molecular assays on cytological samples: an international validation study
202115 citationsauthor #16
Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy
202134 citationsauthor #26
Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer
202148 citationsauthor #13
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer
202116 citationsauthor #6
Prognostic impact of cancer stem cell markers and in colorectal cancer
20210 citationsauthor #5
63O Letrozole and palbociclib versus third generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
20212 citationsauthor #16
G Protein-Coupled Receptors in radioiodine-refractory thyroid cancer in the Era of Precision Medicine.
20215 citationsauthor #6
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer
202129 citationsauthor #12
Abstract PS12-03: Letrozole and palbociclib versus 3rdgeneration chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study
20210 citationsauthor #16
Abstract P2-08-21: Outcomes results of Prosigna® test in early breast cancer patients: Experience of Institut Curie, France
20200 citationsauthor #4
Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology
202043 citationsauthor #16
Prognostic impact of cancer stem cell markers ABCB1, NEO1 and HIST1H2AE in colorectal cancer.
20208 citationsauthor #5
Digital Multiplexed Gene Expression Analysis of mRNA and miRNA from Routinely Processed and Stained Cytological Smears: A Proof-of-Principle Study
20209 citationsauthor #1
161O Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib
20205 citationsauthor #5
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
202099 citationsauthor #24
Abstract P2-14-10: Prosigna® test in clinical routine: Impact on adjuvant chemotherapy decision and medico-economic considerations in France
20201 citationsauthor #4
Abstract P2-02-04: Feasibility of breast cancer risk assessment during check-up in the general population for personalized screening and prevention recommendations: Preliminary results from a dedicated risk clinic
20200 citationsauthor #9
Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?
202012 citationsauthor #6
The bipartite TAD organization of the X-inactivation center ensures opposing developmental regulation of Tsix and Xist
201967 citationsauthor #13
SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation
20194 citationsauthor #15
Protein tyrosine phosphatase 4A3 (PTP4A3/PRL-3) promotes the aggressiveness of human uveal melanoma through dephosphorylation of CRMP2
201921 citationsauthor #7
Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
20197 citationsauthor #27
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
201917 citationsauthor #17
Abstract P6-17-25: PAM50 and CGH-array genomic characterization of HER2-equivocal breast cancers defined by the ASCO/CAP2013 recommendations and response to treatment
20190 citationsauthor #10
PAM50 and CGH-array genomic characterization of HER2-equivocal breast cancers defined by the 2018 ASCO/CAP recommendations
20190 citationsauthor #11
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma
201937 citationsauthor #15
Reference-free transcriptome exploration reveals novel RNAs for prostate cancer diagnosis
201917 citationsauthor #9
A large collection of integrated genomically characterized patient‐derived xenografts highlighting the heterogeneity of triple‐negative breast cancer
201949 citationsauthor #27
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
201848 citationsauthor #14
LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers
201826 citationsauthor #11
Evaluation of a 29 gene classifier for basal/non basal prediction in muscle-invasive bladder cancer FFPE samples.
20180 citationsauthor #4
BRCA2 Loss‐of‐Function and High Sensitivity to Cisplatin‐Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine
20187 citationsauthor #8
Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial
201858 citationsauthor #15
A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts
2018132 citationsauthor #26
The iron chelator deferasirox synergises with chemotherapy to treat triple‐negative breast cancers
201860 citationsauthor #10
Genome-wide identification of genic and intergenic neuronal DNA regions bound by Tau protein under physiological and stress conditions
201846 citationsauthor #5
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
2018143 citationsauthor #19
LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors
201820 citationsauthor #7
Denaturing fixatives are compatible with the NanoString nCounter® platform and the Prosigna® assay.
20171 citationsauthor #7
Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers
201714 citationsauthor #6
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay
201722 citationsauthor #4
Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient‐derived xenografts
201729 citationsauthor #2
Abstract P2-05-04: Evaluation of intra-tumor heterogeneity, test reproducibility and their impact in breast cancer samples assessed by Prosigna™: Results from a decision impact prospective study and a matched case-control study
20170 citationsauthor #5
Evisceration and ocular tumors: What are the consequences?
201712 citationsauthor #7
GENE‐EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA
20174 citationsauthor #21
[Neurotrophic factors for motor neurons: an à la carte menu].
20170 citationsauthor #3
Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges
2017205 citationsauthor #13
Novel combinatorial screening identifies neurotrophic factors for selective classes of motor neurons
201726 citationsauthor #7
Molecular insights into the pathways underlying naked mole-rat eusociality
201714 citationsauthor #3
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers
201730 citationsauthor #3
Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization
201610 citationsauthor #4
Classification of diffuse large b-cell lymphoma (DLBCL) FFPE samples of the GELA LNH2003 program, using Lymph2Cx assay on the nCounter analysis system.
20160 citationsauthor #4
Characterization of breast cancer preclinical models reveals a specific macrophage polarization
20160 citationsauthor #4
Chromatin Regulators as a Guide for Cancer Treatment Choice
201619 citationsauthor #8
Prospective multicenter study of the impact of the Prosigna assay on adjuvant clinical decision-making in women with early stage breast cancer: which patients are the best candidates?
20163 citationsauthor #2
Standardized Whole-Blood Transcriptional Profiling Enables the Deconvolution of Complex Induced Immune Responses.
201689 citationsauthor #9
Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay
201645 citationsauthor #4
Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma
2016104 citationsauthor #5
Abstract OT2-03-02: DI study: Decision impact of the NanoString® Technologies Prosigna™ in early breast cancers
20160 citationsauthor #6
Abstract 1524: Mutations and gene copy number variations landscape of metastases of various cancer types from patients enrolled in the SHIVA trial
20161 citationsauthor #5
Abstract LB-129: Epigenetic regulators to predict docetaxel sensitivity; a guide for treatment choice
20160 citationsauthor #8
MB-77MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA WITH NANOSTRING TECHNOLOGY: A FEASIBILITY STUDY FOR ROUTINE REAL-TIME PROCEDURES.
20160 citationsauthor #2
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
201643 citationsauthor #7
Macroscopic Analysis of Fetus Having Arhinencephaly, Synophthalmia andHoloprosencephaly
20165 citationsauthor #2
Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial
201613 citationsauthor #12
Massively parallel DNA sequencing from routinely processed cytological smears
201620 citationsauthor #6
Abstract 3809: Protein arginine methyltransferase 1 (PRMT1) is a candidate therapeutic target for breast cancers
20160 citationsauthor #8
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
2016103 citationsauthor #14
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: Results of the SHIVA trial.
20153 citationsauthor #14
TIPIN depletion leads to apoptosis in breast cancer cells
201519 citationsauthor #13
Abstract P2-05-06: Identification of specific gene signatures and alternative splice variants using exon array in Inflammatory breast Cancer
20150 citationsauthor #5
Histo‐genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non‐BRCAness high grade ovarian carcinoma
201555 citationsauthor #6
articleA genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
20150 citationsauthor #12

TIMELINE

2007 31 citations

2008 63 citations

2009 17 citations

2010 244 citations

2011 295 citations

2012 525 citations

2013 883 citations

2014 793 citations

2015 1,222 citations

2016 455 citations

2017 357 citations

2018 540 citations

2019 219 citations

2020 177 citations

2021 275 citations

2022 171 citations

2023 52 citations

2024 10 citations

2025 0 citations

2026 0 citations

D. Gentien

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT